Neuroprotective properties of n-phenylacetyl-l-prolylglycine ethyl ester nasal gel in an experimental model of multiple sclerosis equivalent

Authors

  • B.S. Burlaka Zaporizhzhia State Medical University, Department of Drug Technology, Mayakovsky av., 26, Zaporizhzhia, 69035, Ukraine https://orcid.org/0000-0003-4539-7331
  • I.F. Belenichev Zaporizhzhia State Medical University, Department of Pharmacology and Medical Formulations, Mayakovsky av., 26, Zaporizhzhia, 69035, Ukraine https://orcid.org/0000-0003-1273-5314
  • O.O. Nefedov SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine», Department of General and Clinical Pharmacy, V. Vernadsky str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0002-5796-1852
  • O.G. Aliyeva Zaporizhzhia State Medical University, Department of Histology, Cytology and Embryology, Mayakovsky av., 26, Zaporizhzhia, 69035, Ukraine https://orcid.org/0000-0003-1287-674X
  • N.V. Bukhtiyarova Zaporizhzhia State Medical University, Department of Clinical Laboratory Diagnostics, Mayakovsky av., 26, Zaporizhzhia, 69035, Ukraine

DOI:

https://doi.org/10.26641/2307-0404.2020.4.221226

Keywords:

nasal gel, specific activity, cerebroprotectors, n-phenylacetyl-l-prolylglycine ethyl ester

Abstract

The purpose of this research is to study the specific activity of our developed nasal dosage form with n-phenylacetyl-l-prolylglycine ethyl ester. The experiments were performed on 260 white outbred rats weighing 190-220 g. Experimental allergic encephalomyelitis (EAE) was induced by a single subcutaneous inoculation of an encephalitogenic mixture (EHM) in Complete Freund's Adjuvant (CFA) based on 100 mg of homologous spinal cord homogenate; 0.2 ml of CFA (the content of killed mycobacteria 5 mg/ml) and 0.2 ml of physiological saline per animal. There were five groups of animals in the study: 1) intact; 2) control - untreated with EAE, received saline solution; 3) animals with EAE that received basic treatment - methylprednisolone (MP), 3.4 mg/kg, intraperitoneally slowly in saline no more than 1/10 of the CBV rat; 4) animals with EAE treated with MP + Noopept, at a dose of 10 mg/kg; 5) animals with EAE treated with MP + Citicoline (Ceraxon, Ferrer Internacional S.A., Spain) D003U1 series, 500 mg/kg, intragastrically. The in­tegrative functions of rats’ brain with EAE were studied using the “Open Field” method with an arena of own production with dimensions 80x80x35 cm. The study of memory was carried out using the radial labyrinth LE760 (AgnTho's, Sweden). Capture and image recording was carried out using a color video camera SSC-DC378P (Sony, Japan). Video file analysis was performed using Smartv 3.0 software (Harvard Apparatus, USA). As a result of the stu­dies on experimental model of multiple sclerosis with a nasal gel containing ethyl ester of n-phenylacetyl-l-pro­lylglycine revealed the presence of normotimic activity, antidepressant and anxiolytic effects, an increase in the total activity of the central nervous system. The results obtained indicate a high neuroprotective and nootropic activity of the Noopept intranasal gel. By the degree of influence on reducing the number of errors in working memory, the Noopept gel sig­nificantly exceeds monotherapy with methylprednisolone and combination therapy with methylprednisolone and citi­coline. A further study of the effect of the developed nasal gel on the morphofunctional indices of sensorimotor cortical neurons under experimental multiple sclerosis, as well as on the content of HSP70 in the animal brain, is promising.

References

Andreeva NI. [Guidelines for the study of the antidepressant activity of pharmacological substances. Guidelines for the experimental (preclinical) study of new pharmacological substances]. Moskva; 2000;121:126. Russian.

Bojko AN, Stoljarov ID, Petrov AM. [Prospects for new methods for the pathogenetic treatment of mul­tiple sclerosis]. Nevrol. vestnik im. VM Behtereva. 2010;XLII(1):157-9. Russian.

Burlaka BS, Beljenichev IF, Gladyshev VV. [Stu­dy of the effect of surfactants on the release of noopept from the nasal dosage form]. Aktual'ni pytannja farma­cev­tychnoi' ta medychnoi' nauky ta praktyky. 2020;1:105-8. Ukrainian. doi: https://doi.org/10.14739/2409-2932.2020.1.198183

Gusev EI, Demina TL, Bojko AN. [Multiple scle­rosis]. Moskva; 1997. p. 464. Russain.

Chekman IS, Belenichev IF, Gromov LA. [Precli­nical study of the specific activity of potential neuroprotective drugs]. Metod. Rekomendacii GFC MZ Ukrainy. Kyiv; 2010. p. 81.

Zargarova TA, Favorova OO. [Experimental autoimmune encephalomyelitis - a model of multiple sclerosis]. Immunologija. 1999;2:5-8. Russian.

Belenichev IF, et al. [Neuroprotection and neuro­plasticity]. Kiev: Logos; 2015;510. Russian.

Nefedov AA. [Modeling experimental allergic encephalomyelitis as the most adequate model of multiple sclerosis. In: Seredenina SB, Neznanova NG, Zwartau EE, editors. Materials of Vseros. conf. with int. par­ticipation dedicated to the 90th anniversary of the birth of acad. Academy of Medical Sciences of the USSR Artur Viktorovich Valdman "Innovations in pharmacology: from theory to practice"; 2014 October 27-28]. St. Petersburg; 2014. p. 129. Russian

Stefanov AV. [Preclinical studies of drugs]. Kiev: Avicenna; 2002. p. 568. Russian.

Antypenko L, Burlaka B, Belenichev I. Noopept: development and validation of a UV-Vis spectro­photo­metric method for the quantification of (S)-N-pheny­lacetyl-L-prolylglycine ethyl ester in bulk drug substance. Pharmakeftiki. 2008;28(4):161-9.

Crusio WE, Schwegler H. Learning spatial orien­tation tasks in the radial-maze and structural variation in the hippocampus in inbred mice. Behav Brain Funct; 2005;3.

doi: https://doi.org/10.1186/1744-9081-1-3

Gudasheva TA, Ostrovskaya RU, Seredenin SB. Novel Technologies for Dipeptide Drugs Design and their Implantation. Curr Pharm Des. 2018;24(26):3020‐7. doi: https://doi.org/10.2174/1381612824666181008105641

Nadel L, Hardt O. Update on Memory Systems and Processes. Neuropsychopharmacol. 2011;36:251-73 doi: https://doi.org/10.1038/npp.2010.169

Ferrer I, Vidal N. Neuropathology of cerebrovas­cular diseases. Handb Clin Neurol. 2017.145:79‐114. doi: https://doi.org/10.1016/B978-0-12-802395-2.00007-9

Downloads

Published

2020-12-28

How to Cite

1.
Burlaka B, Belenichev I, Nefedov O, Aliyeva O, Bukhtiyarova N. Neuroprotective properties of n-phenylacetyl-l-prolylglycine ethyl ester nasal gel in an experimental model of multiple sclerosis equivalent. Med. perspekt. [Internet]. 2020Dec.28 [cited 2024Nov.14];25(4):31-8. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/221226

Issue

Section

THEORETICAL MEDICINE